![](/img/cover-not-exists.png)
PSS20 COST-UTILITY ANALYSIS OF A PRN (AS NEEDED) TREATMENT SCHEDULE WITH RANIBIZUMAB (LUCENTIS®) IN WET AMD BASED ON CLINICAL EVIDENCE
K Moeremans, L Gerlier, P Mitchell, M Gallagher, G VinczeVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72649-3
File:
PDF, 69 KB
english, 2010